The High-Cost Claim Your Benefits Strategy Isn't Ready For
Are your benefits ready for what's coming? Cell and gene therapies are moving rapidly from the research pipeline into real-world care, and are bringing extraordinary promise for patients and significant clinical and financial complexity for self-insured employers.As these therapies become more prevalent, HR and benefits leaders are navigating a new set of questions with limited precedent: how to support employee access to breakthrough treatments, how to manage financial exposure and oversight, and how to prepare benefit strategies for a category of care still taking shape.In this webinar, industry leaders will offer clarity on how employers can begin to think strategically about readiness, governance, and long-term sustainability, highlighting what matters most today and which capabilities will grow in importance as cell and gene therapies emerge as a distinct high-cost category